Search

Potassium bitartrate

Potassium bitartrate has a long history of medical use as a laxative administered as a rectal suppository and is an approved third-class OTC drug in Japan. … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

Altanserin

Altanserin has a monoisotopic molecular weight of 411.14 Da. … Altanserin is a small molecule drug. The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist.

Atrasentan

Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

Vicasinabin

Vicasinabin has a monoisotopic molecular weight of 358.2 Da. … Vicasinabin is a small molecule drug.

Ofirnoflast

Ofirnoflast has a monoisotopic molecular weight of 501.15 Da. … Ofirnoflast is a small molecule drug. The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor.

Calcium phosphate dihydrate

Bicalutamide

It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.

Sipuleucel-T

Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

Umeclidinium

Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.

Propranolol

[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904] … Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.